Year: 2023
Type: article
Abstract: Tezepelumab, which inhibits thymic stromal lymphopoietin, demonstrated efficacy in the phase 2 PATHWAY and phase 3 NAVIGATOR randomized, placebo-controlled clinical trials in diverse subgroups of patients with severe asthma as defined by baseline peripheral eosinophil counts and fractional exhaled nitric oxide (Feno) levels. Corren et al (Am J Respir Crit Care Med 2023 Apr 4; https://doi.org/10.1164/rccm.202210-2005OC) performed a post hoc pooled analysis of these 2 studies to examine the efficacy of tezepelumab in additional subgroups.
Authors: Marc E. Rothenberg, Jean Bousquet
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
OpenAlex ID: W4383265815